622 related articles for article (PubMed ID: 33774178)
1. Molecular characterization of interactions between the D614G variant of SARS-CoV-2 S-protein and neutralizing antibodies: A computational approach.
Kwarteng A; Asiedu E; Sylverken AA; Larbi A; Sakyi SA; Asiedu SO
Infect Genet Evol; 2021 Jul; 91():104815. PubMed ID: 33774178
[TBL] [Abstract][Full Text] [Related]
2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
[TBL] [Abstract][Full Text] [Related]
3. Structural basis for accommodation of emerging B.1.351 and B.1.1.7 variants by two potent SARS-CoV-2 neutralizing antibodies.
Cerutti G; Rapp M; Guo Y; Bahna F; Bimela J; Reddem ER; Yu J; Wang P; Liu L; Huang Y; Ho DD; Kwong PD; Sheng Z; Shapiro L
Structure; 2021 Jul; 29(7):655-663.e4. PubMed ID: 34111408
[TBL] [Abstract][Full Text] [Related]
4. The SARS-CoV-2 Y453F mink variant displays a pronounced increase in ACE-2 affinity but does not challenge antibody neutralization.
Bayarri-Olmos R; Rosbjerg A; Johnsen LB; Helgstrand C; Bak-Thomsen T; Garred P; Skjoedt MO
J Biol Chem; 2021; 296():100536. PubMed ID: 33716040
[TBL] [Abstract][Full Text] [Related]
5. Impact of Genetic Variability in ACE2 Expression on the Evolutionary Dynamics of SARS-CoV-2 Spike D614G Mutation.
Huang SW; Miller SO; Yen CH; Wang SF
Genes (Basel); 2020 Dec; 12(1):. PubMed ID: 33374416
[TBL] [Abstract][Full Text] [Related]
6. Priming of SARS-CoV-2 S protein by several membrane-bound serine proteinases could explain enhanced viral infectivity and systemic COVID-19 infection.
Fuentes-Prior P
J Biol Chem; 2021; 296():100135. PubMed ID: 33268377
[TBL] [Abstract][Full Text] [Related]
7. SARS-CoV-2 escape from a highly neutralizing COVID-19 convalescent plasma.
Andreano E; Piccini G; Licastro D; Casalino L; Johnson NV; Paciello I; Dal Monego S; Pantano E; Manganaro N; Manenti A; Manna R; Casa E; Hyseni I; Benincasa L; Montomoli E; Amaro RE; McLellan JS; Rappuoli R
Proc Natl Acad Sci U S A; 2021 Sep; 118(36):. PubMed ID: 34417349
[TBL] [Abstract][Full Text] [Related]
8. Molecular insights into the binding interactions and energetics of the omicron spike variant with hACE2 and a neutralizing antibody.
Kumar V; Shefrin S; Sundar D
J Struct Biol; 2024 Jun; 216(2):108087. PubMed ID: 38494148
[TBL] [Abstract][Full Text] [Related]
9. Characterization of Entry Pathways, Species-Specific Angiotensin-Converting Enzyme 2 Residues Determining Entry, and Antibody Neutralization Evasion of Omicron BA.1, BA.1.1, BA.2, and BA.3 Variants.
Neerukonda SN; Wang R; Vassell R; Baha H; Lusvarghi S; Liu S; Wang T; Weiss CD; Wang W
J Virol; 2022 Sep; 96(17):e0114022. PubMed ID: 36000843
[TBL] [Abstract][Full Text] [Related]
10. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRs.
Choudhury A; Mukherjee S
J Med Virol; 2020 Oct; 92(10):2105-2113. PubMed ID: 32383269
[TBL] [Abstract][Full Text] [Related]
11. Effect of SARS-CoV-2 B.1.1.7 mutations on spike protein structure and function.
Yang TJ; Yu PY; Chang YC; Liang KH; Tso HC; Ho MR; Chen WY; Lin HT; Wu HC; Hsu SD
Nat Struct Mol Biol; 2021 Sep; 28(9):731-739. PubMed ID: 34385690
[TBL] [Abstract][Full Text] [Related]
12. Structures of the Omicron spike trimer with ACE2 and an anti-Omicron antibody.
Yin W; Xu Y; Xu P; Cao X; Wu C; Gu C; He X; Wang X; Huang S; Yuan Q; Wu K; Hu W; Huang Z; Liu J; Wang Z; Jia F; Xia K; Liu P; Wang X; Song B; Zheng J; Jiang H; Cheng X; Jiang Y; Deng SJ; Xu HE
Science; 2022 Mar; 375(6584):1048-1053. PubMed ID: 35133176
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Critical Determinants of ACE2-SARS CoV-2 RBD Interaction.
Brown EEF; Rezaei R; Jamieson TR; Dave J; Martin NT; Singaravelu R; Crupi MJF; Boulton S; Tucker S; Duong J; Poutou J; Pelin A; Yasavoli-Sharahi H; Taha Z; Arulanandam R; Surendran A; Ghahremani M; Austin B; Matar C; Diallo JS; Bell JC; Ilkow CS; Azad T
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668756
[TBL] [Abstract][Full Text] [Related]
14. Epitope Classification and RBD Binding Properties of Neutralizing Antibodies Against SARS-CoV-2 Variants of Concern.
Deshpande A; Harris BD; Martinez-Sobrido L; Kobie JJ; Walter MR
Front Immunol; 2021; 12():691715. PubMed ID: 34149735
[TBL] [Abstract][Full Text] [Related]
15. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity.
Ozono S; Zhang Y; Ode H; Sano K; Tan TS; Imai K; Miyoshi K; Kishigami S; Ueno T; Iwatani Y; Suzuki T; Tokunaga K
Nat Commun; 2021 Feb; 12(1):848. PubMed ID: 33558493
[TBL] [Abstract][Full Text] [Related]
16. In Silico Investigation of the New UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 Variants with a Focus at the ACE2-Spike RBD Interface.
Villoutreix BO; Calvez V; Marcelin AG; Khatib AM
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33567580
[TBL] [Abstract][Full Text] [Related]
17. Tinocordiside from
Balkrishna A; Pokhrel S; Varshney A
Comb Chem High Throughput Screen; 2021; 24(10):1795-1802. PubMed ID: 33172372
[TBL] [Abstract][Full Text] [Related]
18. Nanoluciferase complementation-based bioreporter reveals the importance of N-linked glycosylation of SARS-CoV-2 S for viral entry.
Azad T; Singaravelu R; Taha Z; Jamieson TR; Boulton S; Crupi MJF; Martin NT; Fekete EEF; Poutou J; Ghahremani M; Pelin A; Nouri K; Rezaei R; Marshall CB; Enomoto M; Arulanandam R; Alluqmani N; Samson R; Gingras AC; Cameron DW; Greer PA; Ilkow CS; Diallo JS; Bell JC
Mol Ther; 2021 Jun; 29(6):1984-2000. PubMed ID: 33578036
[TBL] [Abstract][Full Text] [Related]
19. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
[TBL] [Abstract][Full Text] [Related]
20. Distinct shifts in site-specific glycosylation pattern of SARS-CoV-2 spike proteins associated with arising mutations in the D614G and Alpha variants.
Kuo CW; Yang TJ; Chien YC; Yu PY; Hsu SD; Khoo KH
Glycobiology; 2022 Feb; 32(1):60-72. PubMed ID: 34735575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
